Acquired resistance to chemotherapy is the major obstacle to cure of s
mall cell lung cancer (SCLC). Some of the most active drugs in the tre
atment of this tumor exert their cytotoxicity by interacting with the
nuclear enzyme topoisomerase II (topo II), which in mammalian cells oc
curs in two isoforms, alpha and beta. We examined the relationship bet
ween levels of topo II alpha and beta and drug response in a panel of
25 unselected SCLC cell lines. Chemosensitivity to several topo II-int
eractive drugs, as well as other chemotherapeutic agents, was quantita
ted previously using a modified MTT assay. Topo II levels were determi
ned by immunoblot analysis of whole cell lysates, with topo II alpha a
nd beta isoform-specific antibodies, and results were expressed relati
ve to levels found in NCI-H209 cells which had the highest topo II alp
ha in this series of cell lines. Levels of topo II alpha and beta mRNA
were determined by Northern blotting. Pearson correlation analysis wa
s used to determine the significance of the relationship between topo
II alpha and beta levels and response to the various chemotherapeutic
drugs, as well as the treatment history of the patients from whom the
cell lines were derived. These analyses revealed an inverse correlatio
n between topo II alpha levels and resistance to all of the tested dru
gs, including several drugs which are not known to interact with topo
II. This correlation was statistically significant for doxorubicin, ci
splatin, epirubicin, melphalan, nitrogen mustard, and vinblastine. Wit
h one exception (cisplatin), there were no significant correlations be
tween topo II beta levels and drug response. There was no significant
correlation between topo II alpha and beta levels and treatment histor
y. Taken together, our results are consistent with the hypothesis that
levels of topo II alpha are important determinants of drug response i
n SCLC.